Market Overview

The global CAR T-cell therapy market is set for substantial expansion, projected to exceed USD 27.5 billion by 2033, up from USD 2.7 billion in 2025, reflecting a robust CAGR of 26.2% from 2025 to 2033.

CAR T-cell therapy is a revolutionary, personalized treatment that leverages body’s immune system to precisely target and destroy cancer cells. The process begins with T-cell extraction, where T cells are harvested from the patient’s blood. These cells are then genetically engineered in a laboratory to express specialized receptors capable of recognizing cancer-specific antigens. Once modified, the T cells undergo expansion, multiplying into hundreds of millions. Finally, the engineered cells are reinfused into the patient, where they seek out and eliminate cancer cells with remarkable precision. This targeted approach not only enhances treatment efficacy but also significantly improves patient outcomes and quality of life (QoL). Currently, most of the available CARTs target hematological cancer. Their potential in treating solid tumors is being explored.  

Hematological cancers have seen a steady rise in prevalence, significantly driving the demand for advanced treatments like CAR T-cell therapy in relapsed/refractory (r/r) patients. In the United States alone, approximately every three minutes, one person is diagnosed with leukemia, lymphoma, or myeloma. As of recent estimates, around 1,698,339 individuals in the United States, are either living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs).  
 
For most patients diagnosed with aggressive blood cancers, the first line of defense involves chemotherapy and immunotherapy. If patients relapse posts these treatments, they may rely on salvage chemotherapy or stem cell transplants. CAR T-cell therapy comes into play after patients fail to respond to multiple lines of earlier conventional therapies. CAR T-cell therapy is stratified based on tumor-specific biomarkers such as CD19 and BCMA. Patients with high biomarker expression may receive standard CAR-T therapy, while those with lower expression might benefit from enhanced CAR-T constructs or combination therapies. 

Since the groundbreaking approvals of Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta), many CAR T-cell products have been approved by the United States Food and Drug Administration (FDA) for various relapsed or refractory hematologic malignancies. The success of these therapies is reflected in their market performance: 

• Yescarta generated USD 1.4 billion in sales in 2023, with over 1,300 patients treated. A mjority of its sales being attributed United States followed by Europe
• Kymriah achieved USD 443 million in sales in 2024 with strong performance in United States for pALL (paediatric acute lymphoblastic leukemia) and FL in ex- United States market
• Following the pattern of well-established CAR T-cell therapy like Yescarta and Kymriah, new launches like Carvykti also witnessed net trade sales of USD 500 million within a year of the launch

Such sales figures are a prominent proof of CAR T-cell therapy demand by the haematological cancer patients. Globally, CAR T-cell therapy has been administered to more than 34,000 eligible patients. However, high cost of CAR T-cell therapy remains a significant barrier to broader adoption. In 2023, the list price for Yescarta was approximately USD 424,000 per infusion, while Tecartus was priced at USD 533,523 per infusion. 

However, favorable reimbursement is acting as a boon for the market growth. Multiple CPT codes have been established for CAR T-cell therapy. These include 0537T (for harvesting of blood-derived T lymphocytes) and 0540T (for administration of autologous CAR T-cells). Manufacturers also have patient assistance programs covering lodging, travelling, and emotional wellness of patients. Programs like Kite Konnect by Gilead supports patients throughout their patient journey. It helps patients choose the right treatment center, supports them for reimbursement and logistics, etc.  

Complex manufacturing processes complicate scalability, and severe side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) require careful management. This is another barrier in the adoption of the CAR T-cell therapy. Furthermore, while CAR T-cell therapy is available in developed countries that offer reimbursement programs, it remains largely inaccessible in developing countries due to affordability issues and limited healthcare infrastructure. 

Conclusively, CAR T-cell therapy represents an emerging frontier in personalized cancer treatment, offering life-saving potential for patients who have exhausted conventional options. As accessibility improves, the impact of this breakthrough therapy is poised to grow, bringing new optimism to the fight against blood cancers.

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Drivers: Rising Hematologic Malignancies Drive Demand for CAR T-Cell Therapy, While Research Expands into Solid Tumors
Hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), B-cell lymphomas, and T-cell lymphoblastic leukemia, are the fifth most prevalent cancer type worldwide. According to the Leukemia and Lymphoma Society, in 2024, the United States recorded 89,190 new cases of lymphoma, 62,770 cases of leukemia, and 35,780 cases of myeloma. Collectively, these cancers were expected to cause 57,260 deaths, with a higher mortality rate in males compared to females. Also, males have higher incidence Vs females. Of the total incident cases (161,050) reported from 2016-2020, 56% of cases are reported to be in men Vs 44% in women.  By age, 40-64 years age group has highest incidence for lymphomas and myeloma. However, in leukaemia 75+ years group had highest incidence.

Such statistics highlight the urgent need for innovative treatment options like CAR T-cell therapy. As per a research letter published in the Blood Advances journal, the eligibility of hematological cancer patients for CAR T-cell therapy increased from 2.7% in 2017 to 3.9% in 2023. This increase may be attributed to government support and favorable reimbursement policies, which have expanded access to these life-saving treatments. 

While CAR T-cell therapy has shown exceptional success in treating hematologic cancers, research is increasingly focusing on its potential application in solid tumors. Unlike blood cancers, solid tumors present unique challenges, such as tumor heterogeneity and an immunosuppressive tumor microenvironment, which can limit the effectiveness of CAR T-cells. To overcome these barriers, scientists are exploring novel antigen targets and refining CAR designs to improve tumor infiltration and persistence. Companies like ACROBiosystems are at the forefront of this effort, developing a range of solid tumor-related target proteins, including MSLN, GPC3, FAP, HER2, and EGFRvIII. Such efforts holds the future of treating solid tumors with CAR T-cell therapy. 

Restraint: High Costs and Complex Manufacturing Hinder CAR T-Cell Therapy Accessibility 
One of the major challenges faced by CAR-T cell therapies is their high cost and complex manufacturing process. While breakthrough treatments like Kymriah have demonstrated impressive efficacy in B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL), their financial burden remains a significant barrier. The list price for CAR-T therapies such as Kymriah ranges from USD 373,000 to USD 475,000 per infusion, excluding additional expenses for inpatient hospitalization, toxicity management, and follow-up care. When these factors are considered, the total cost per patient can exceed USD 500,000, making affordability a critical concern. Even with reimbursement programs and patient assistance services, out-of-pocket expenses, such as deductibles, co-payments, and co-insurance, can pose a challenges. 

Beyond cost, the manufacturing process of CAR-T therapy is highly intricate and resource-intensive. It requires specialized instruments, reagents, and consumables, along with stringent quality control measures to ensure safety and efficacy. The production cost alone can surpass USD 100,000 per patient. Additionally, accessibility is limited due to the small number of certified therapy centers, which must be equipped with leukapheresis facilities, cell storage units, and the capacity to manage acute complications, including intensive care. As of July 2024, it was identified that there were only 311 certified CAR-T cell centers across the United States. Establishing and maintaining such centers demands substantial investment, and the risk of contamination during production remains a constant challenge, as even minor deviations from a sterile environment can compromise the final product. 

Opportunity: Genome Editing, Dual-Targeting is Revolutionising CAR T-Cell Therapy Market Beyond Oncology
Advancements in genome editing and cell engineering technologies, such as CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs), are revolutionizing CAR-T cell therapies by enabling precise genetic modifications. These tools allow researchers to enhance the potency, durability, and safety of CAR-T treatments by optimizing T-cell function and reducing adverse effects. Genome editing works by inducing double-stranded breaks at targeted DNA sites, which can be repaired through nonhomologous end-joining, introducing small insertions or deletions that disrupt gene function, or homology-directed repair, which, in the presence of a donor DNA template, enables precise gene correction or insertion at the desired site. These editing techniques are particularly valuable for modifying T-cells in CAR-T therapy, improving targeting accuracy, preventing antigen escape, and enhancing persistence in the body. 

While single-target CAR-T therapies have significantly improved survival rates in hematologic malignancies, many patients still experience relapse due to antigen escape. To address this, dual-targeting CAR-T therapies have emerged, designed to recognize multiple cancer markers and reduce the likelihood of treatment resistance. Clinical data on dual-targeting CAR-T therapies confirm their improved efficacy and safety, though further refinement is needed to optimize bispecific CAR structures and boost T-cell transduction efficiency.

Beyond oncology, CAR-T technology is now being explored for autoimmune diseases. Researchers are investigating CAR-T cells that selectively eliminate overactive B-cells, with the goal of achieving long-term, drug-free remission in conditions such as lupus and rheumatoid arthritis. These developments highlight the expanding potential of CAR-T cell therapy, paving the way for innovative treatments across various medical fields. 

Segmental analysis 

By Indication: Lymphoma Leads, While Leukemia and Multiple Myeloma Gain Traction
By indication, CAR T-cell therapy is primarily used to treat hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, with lymphoma holding the largest market share at around 60%. This dominance is driven by its higher incidence and the availability of multiple FDA-approved therapies, including Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), Breyanzi (lisocabtagene maraleucel), and Tecartus (brexucabtagene autoleucel).

While lymphoma remains the primary focus, leukemia and multiple myeloma are seeing increased adoption. Approved CAR T-cell therapy for leukemia include Kymriah, Tecartus, and Aucartyl (obecabtagene autoleucel). Notably, Kymriah is indicated for Acute Lymphoblastic Leukemia (ALL) in patients up to 25 years old who are refractory or have relapsed multiple times.

For multiple myeloma, Carvykti (ciltacabtagene autoleucel) was approved in February 2022 for patients with at least one prior therapy, followed by Abecma (idecabtagene vicleucel) in April 2024 for those with two or more prior treatments. These approvals represent major advancements, expanding CAR T-cell therapy beyond lymphoma and offering new options for relapsed/refractory multiple myeloma.

Ongoing research and future approvals continue to be the key to broaden CAR T-cell therapy’s reach, providing innovative treatments for patients with limited alternatives.

Table: FDA-Approved CAR T-Cell Therapies: Indications, Approval Timeline, Pivotal Trials, and Costs

Source: FDA, Regulatory Bodies, Journals, etc. 

By Source: Autologous CAR T-Cell Therapy Leads the Market, While Allogeneic Therapies Gain Momentum 
CAR T-cell therapy is classified into two types based on its source: autologous and allogeneic. Autologous CAR T-cell therapy currently dominates the market with a share of more than 90% due to its established clinical success. This approach involves extracting a patient’s T cells, genetically modifying them to express a chimeric antigen receptor (CAR) targeting specific cancer antigens and reinfusing them after expansion. To maximize effectiveness, patients undergo a pre-conditioning chemotherapy regimen that optimizes CAR T-cell activity. Personalized treatments like Yescarta and Kymriah have demonstrated strong clinical outcomes, solidifying autologous CAR T-cell therapy as the standard in the market.

Allogeneic CAR T-cell therapy, on the other hand, is still in the experimental phase but holds promise for the future. Unlike autologous therapy, which requires a lengthy and patient-specific manufacturing process, allogeneic therapy uses T cells from healthy donors. These cells are genetically modified, stored in large batches, and designed to be available as “off-the-shelf” treatments, potentially enabling faster administration and broader accessibility. However, challenges such as graft-versus-host disease (GvHD) and immune rejection have limited its progression toward commercialization. Researchers are actively working to overcome these barriers using advanced gene-editing technologies like TALENs and CRISPR-Cas9 to enhance safety and efficacy.

By Type of Therapy: Monotherapy Leads the Market, While Combination Strategies Shape the Future
CAR T-cell therapy is broadly categorized into monotherapy and combination therapy. Monotherapy currently dominates the CAR T-cell therapy market, particularly in hematologic malignancies. Currently it holds more than 60% of the market share. This approach involves genetically engineering a patient’s T-cells to recognize and attack cancer cells and has demonstrated high remission rates. Treatments such as Yescarta and Kymriah have set benchmarks for success by precisely targeting cancer cells without the need for supplementary therapies. However, challenges like antigen escape, T-cell exhaustion, and inconsistent persistence can limit long-term efficacy, creating opportunities for more advanced treatment strategies.

To address these limitations, research into combination therapies is gaining traction. In hematologic malignancies, one promising approach is integrating CAR T-cell therapy with checkpoint inhibitors like PD-1/PD-L1 blockers, which prevent immune evasion and improve CAR T-cell persistence. 

Although monotherapy continues to lead the CAR T-cell therapy market, advancements in combination strategies could significantly expand its therapeutic reach. As research progresses, refining these approaches may enhance efficacy, reduce relapse rates, and improve patient outcomes across a broader range of cancers.

By Administration Settings: Inpatient Care Remains Standard, While Outpatient Adoption Rises
CAR T-cell therapy is administered in either inpatient or outpatient settings. Inpatient administration currently dominates the market due to the need for monitoring of adverse events such as Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Currently, the segment holds more than 70% of the market share. These complications as triggered by the rapid expansion of CAR T-cells and the resulting cytokine surge, require immediate medical intervention. This makes inpatient care as the standard approach to ensure patient safety.

However, outpatient administration is emerging as a cost-effective alternative. Recent research suggests that, with proper patient selection and structured monitoring, outpatient care can provide comparable safety and efficacy. The shift from outpatient to inpatient CAR T-cell therapy administration can result in a total cost decrease by 40% (saving on hospitalisation, office visits, and procedural expense). 

As clinical protocols evolve and toxicity management improves, outpatient administration is expected to gain traction. By reducing hospitalization costs and increasing accessibility without compromising patient outcomes, it has the potential to reshape the delivery of CAR T-cell therapy in the future.

By Product: Yescarta Leads the CAR T-Cell Therapy Market as Sales Surge, While Competition Intensifies
CAR T-cell therapy market has several approved products including ABECMA, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta. Among them, Yescarta (axicabtagene ciloleucel) by Kite Pharma dominated the market in 2024, generating USD 1.6 billion in sales; a 5% increase from 2023. This is driven by a rising demand outside the United States. Its widespread adoption stems from approvals across multiple indications; large B-cell lymphoma (LBCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Apart from this established physician trust and favourable reimbursement policies have reinforced its leadership.

Kymriah (tisagenlecleucel) by Novartis also demonstrated strong performance, reaching USD 508 million in sales in 2023. Its success is attributed to high adoption in paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) in the United States, along with expanding international use in follicular lymphoma.

Abecma (idecabtagene vicleucel) by Bristol Myers Squibb, achieved USD 472 million in revenue in 2023, while Carvykti (ciltacabtagene autoleucel) by Johnson & Johnson, reported a sales of USD 500 million, reflecting rapid market growth. Tecartus (brexucabtagene autoleucel), another CAR T-cell therapy from Kite Pharma generated USD 403 million in 2023.

As CAR T-cell therapy adoption accelerates and indications broaden, the competitive landscape continues to evolve. Ongoing innovation, increased accessibility, and clinical advancements are driving market expansion, solidifying CAR T-cell therapies as a transformative force in oncology.

 To Understand More About this Research:  Request A Free Sample 

By Region: North America Leads CAR T-Cell Adoption; Asia-Pacific and Emerging Markets Accelerate
CAR T-cell therapy adoption varies across four key regions: North America, Europe, Asia-Pacific, and the Middle East & Africa. North America leads the market, driven by early approvals, a strong biotech industry, and well-established reimbursement policies. The United States dominates, with therapies like Kymriah (2017) and Yescarta benefiting from Medicare’s MS-DRG 018 program, which provides a base reimbursement of USD 247,939 for inpatient CAR T-cell treatment. 
In Canada as well, several CAR T-cell therapies that cost around USD 500K can be covered Ontario Health funding, i.e., as per the eligibility requirements set by Health Canada. However, this is restricted with only 6 of the 10 Canadian provinces having authorised public reimbursement. Instead, Canadian government is focussing on investing in public development of made-in-Canada CAR T-cell therapies.  

Europe follows closely, with Germany and France leading in adoption due to favourable regulatory frameworks that expand patient access. While reimbursement policies vary by country, they are steadily improving, supporting wider availability of CAR T-cell therapies. 

The Asia-Pacific region, though still behind North America and Europe, is experiencing rapid growth fuelled by increasing investments, clinical research, and regulatory advancements. China and Japan are at the forefront, with local biotech firms actively developing CAR T-cell therapies. As regulatory pathways become clearer, access is expected to expand. Developing countries, such as India, face adoption challenges due to infrastructure and limited public insurance. However, progress is evident. In October 2023, India’s CDSCO approved NexCAR 19 (Actalycabtagene autoleucel), developed by ImmunoACT in collaboration with Tata Memorial Centre. As India’s first CAR T-cell therapy, NexCAR 19 is priced significantly lower at ~ USD 34,000 - 45,000, i.e., at 1/10 cost of its global counterparts. Approval was based on two small clinical trials involving 64 patients with advanced lymphoma or leukemia, marking a major step toward broader access in resource-limited settings.

The Middle East & Africa holds the smallest market share, mainly due to limited healthcare infrastructure, particularly in African nations. However, GCC countries like Saudi Arabia and the UAE are emerging as key players, investing in advanced treatments and expanding access to CAR T-cell therapy.

Key Recent Developments in CAR-T Cell Therapy Market

Feb 21, 2025: bluebird bio Entered a Definitive Agreement for Acquisition by Carlyle and SK Capital

• Bluebird’s Stockholders will receive USD 3.00 per share in cash, along with a contingent value right (CVR) of USD 6.84 per share in cash, which will be payable upon meeting a specified net sales milestone, subject to the fulfilment of offer conditions
• Upon closing of the agreement, David Meek (former CEO of Mirati Therapeutics and Ipsen) is expected to become bluebird’s CEO

Febr 22, 2024:AstraZeneca Completed Acquisition of Gracell Biotechnologies

• AstraZeneca acquired Gracell Biotechnologies, strengthening its cell therapy pipeline with GC012F (a FasTCAR-enabled BCMA and CD19 dual-targeting autologous CAR-T therapy)
• The upfront cash component of the consideration equates to a transaction value of approximately USD 1.0 billion. When combined with potential contingent value payments, if achieved, the total transaction value could reach approximately USD 1.2 billion

Nov 20,2024: Vyriad and Novartis Collaboration

• Vyriad, Inc. and Novartis entered a strategic collaboration to develop in vivo CAR-T cell therapies
• The partnership leveraged Vyriad’s targeted lentiviral vector platform and Novartis’ expertise in cell therapy innovation to identify and develop in vivo CAR T-cell therapy candidates
  • The clinical development will be taken care by Novartis
  • Furthermore, under the agreement Vyriad will receive an upfront payment alongside with postulates for milestone payments, and tiered royalties for each program

Dec 06,2023: BMS’s Abecma Became First CART in Japan to be Approved for Treating R/R MM (Multiple Myeloma) Patients in Earlier Lines of Treatment

• BMS KK received a marketing and manufacturing approval for Abecma against its sNDA for R/R MM patients who have at least received two lines of therapies (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 Ab)

Key Players In The Global CAR T-Cell Therapy Market: 

• Novartis AG
• Bluebird Bio, Inc.
• Cellectis
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Juno Therapeutics, Inc.
• Celyad Oncology
• Celgene Corporation
• Sorrento Therapeutics, Inc.
• Miltenyi Biotech
• Intellia Therapeutics
• Pfizer, Inc.
• Autolus Therapeutics
• Gilead Sciences, Inc. (Kite Pharma Inc.)
• Cartesian Therapeutics, Inc.
• Caribou Biosciences, Inc.
• Other Prominent Players

Market Segmentation Overview

By Indication

• Leukemia
• Lymphoma
• Myeloma

By Source 

• Autologous
• Allogenic

By Type of Therapy

• Monotherapy
• Combination therapy

By Product

• ABECMA
• Breyanzi
• Carvykti
• Kymriah
• Tecartus
• Yescarta

By Administration Setting

• Inpatient
• Outpatient 

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America